Accelerate your RNAi research with custom-designed siRNAs optimized for potency, specificity, and stability.
Small interfering RNAs (siRNAs) are powerful tools for sequence-specific gene silencing, enabling researchers to dissect gene function, validate therapeutic targets, and develop RNA-based therapies. Our siRNA design and synthesis service combines advanced bioinformatic algorithms, high-quality chemical synthesis, and rigorous quality control to deliver siRNAs that meet the demands of both basic research and preclinical development.
Poorly designed siRNAs often result in inconsistent or irreproducible knockdown, wasting valuable research resources. We address these challenges through intelligent sequence design that minimizes off-target effects, improves nuclease resistance, and enhances transfection efficiency. Our platform integrates structural accessibility prediction, thermodynamic optimization, and off-target filtering to generate siRNA candidates with high silencing activity and specificity.
From individual sequences to large-scale libraries and chemically modified conjugates, our service is modular and scalable. Whether you need a single siRNA for target validation or a genome-wide library for high-content screening, we provide the technical expertise and quality assurance to support your RNAi workflow.
Key Features
Custom siRNA Design and Synthesis
Our design service uses proprietary algorithms to analyze target mRNA structure, GC content, and thermodynamic properties, ensuring high silencing efficiency and minimal off-target potential. Each sequence is synthesized on automated solid-phase platforms under stringent quality controls. Deliverables include lyophilized or solution-form siRNA, with optional annealing into duplexes.
Chemical Modifications and Conjugates
To improve stability and delivery, we offer a wide range of chemical modifications including 2′-O-methyl, 2′-fluoro, locked nucleic acids (LNA), and phosphorothioate backbones. We also provide covalent conjugates with lipids, peptides, or fluorescent dyes (FAM, Cy3, Cy5) for tracking and targeting. Modified siRNAs exhibit enhanced nuclease resistance and improved pharmacokinetic profiles.
High-Throughput Libraries and Screening
Predesigned siRNA libraries targeting specific pathways, disease gene families, or entire genomes are available for large-scale functional screens. Our screening service integrates automated liquid handling, high-content readouts, and data analytics to rapidly identify the most effective silencing candidates. This accelerates target discovery and gene validation studies.
Quality Control and Validation
Every siRNA batch undergoes rigorous QC including HPLC or PAGE purity analysis, LC-MS identity confirmation, and endotoxin testing. Annealing efficiency is verified before shipment. For custom projects, optional knockdown validation in a cell line of choice can be included. A comprehensive QC report accompanies each order, ensuring reproducibility across experiments.
Product Formats
Our siRNA service covers a range of formats to match different experimental needs. From single sequences to pooled libraries, each format is produced with consistent quality and documentation.
Individual siRNA: Single sequence synthesized at scales from nmol to gram. Ideal for target validation or dose-response studies. Available with or without chemical modifications.
siRNA Pools: Pools of multiple siRNAs targeting the same gene to increase silencing robustness and reduce single-sequence variability. Suitable for rapid phenotypic screening.
siRNA Libraries: Pre-designed libraries covering whole genomes, drug targets, or specific signaling pathways. Enable high-throughput functional genomics and synthetic lethality screens.
Chemically Modified siRNA: Incorporation of 2′-O-methyl, 2′-fluoro, LNA, or phosphorothioate bonds to enhance stability and reduce immunogenicity. Designed for in vivo applications and long-term silencing.
Labeled siRNA: Fluorescence-tagged siRNAs (e.g., FAM, Cy3, Cy5) for tracking cellular uptake, intracellular distribution, and endosomal escape. Valuable for transfection optimization and imaging.
Workflow
Our workflow proceeds through five phases, from target analysis to final product delivery.
Target Analysis and siRNA Design: You provide the target gene sequence (cDNA or mRNA accession). Our bioinformatics team designs multiple siRNA candidates using off-target filtering, specificity scoring, and thermodynamic optimization. Results include ranked sequences with predicted metrics.
Candidate Review and Selection: We present a design report with candidate sequences for your review. You select the preferred sequences or request additional designs. Adjustments for modification patterns or labeling are finalized at this stage.
Chemical Synthesis and Purification: Selected siRNAs are synthesized on solid-phase synthesizers with defined chemical modifications. After cleavage and deprotection, the crude product is purified by HPLC or PAGE to achieve target purity (>90% as agreed per project).
Quality Control Characterization: Purified siRNAs are analyzed by LC-MS for molecular weight confirmation, by HPLC for purity, and by UV spectrophotometry for concentration. Annealing efficiency of duplex siRNA is verified by gel electrophoresis or ion-exchange chromatography.
Packaging and Shipment: Final product is lyophilized or supplied in RNase-free water or buffer, as specified. Each order includes a Certificate of Analysis with QC data. Shipment is made on dry ice for solution formats or at ambient for lyophilized material.
Quality Assurance
Each siRNA product is subjected to a set of standardized QC assays to ensure batch-to-batch consistency and reliable biological performance. Purity is assessed by reversed-phase HPLC or denaturing PAGE, with a minimum purity threshold defined per project (typically ≥90% for standard products). Identity is confirmed by LC-MS mass spectrometry, verifying the exact molecular weight of the full-length oligonucleotide. Concentration is determined by UV absorbance at 260 nm, and annealing efficiency for duplex formulations is verified by gel electrophoresis or ion-exchange chromatography.
For modified siRNAs, additional QC may include fluorescence verification (for labeled products) and endotoxin testing (LAL assay) for in vivo applications. All QC data are compiled in a Certificate of Analysis provided with the shipment. Optional third-party validation (e.g., knockdown efficiency in a target cell line) can be scoped as an add-on service.
Why Choose Us
Advanced Bioinformatic Design: Our design algorithms consider target mRNA secondary structure, seed region specificity, and off-target potential to maximize silencing efficiency and reduce artifacts.
Custom Chemical Modifications: A range of modifications—2′-O-methyl, 2′-fluoro, LNA, phosphorothioate—and conjugates (lipid, peptide, fluorescent dye) are available to tailor siRNAs for stability, delivery, or tracking.
Scalable Synthesis: From nanomole to gram scale, our synthesis platform accommodates both small-scale research needs and larger preclinical quantities, with consistent QC across batches.
Rigorous Quality Assurance: Every batch undergoes HPLC/LC-MS purity and identity checks, with optional endotoxin and knockdown validation. Full documentation supports reproducible experiments.
Backed by Creative Biogene: All projects are delivered under Creative Biogene's ISO-aligned quality system, with dedicated project management, milestone-based reporting, and full intellectual property protection for your data.
Commonly Used Cell Types for siRNA Transfection
RNA can be delivered to a wide variety of cell types.
Mammalian Cell Lines: HEK293, HeLa, A549, HepG2, MCF-7, and many others. Transfection conditions are optimized per cell line to achieve >80% knockdown efficiency.
Primary Cells: Primary fibroblasts, macrophages, endothelial cells, and hepatocytes. Specialized transfection reagents and protocols are used to maintain cell viability and achieve effective silencing.
Stem Cells: Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs). siRNA delivery is optimized to minimize toxicity and preserve pluripotency during gene silencing studies.
Immune Cells: T cells, B cells, dendritic cells, and natural killer (NK) cells. Lipid-based or electroporation methods are tailored for efficient siRNA uptake in suspension cells.
Contact Us
Whether you need a single validated siRNA for target confirmation, a chemically modified construct for in vivo studies, or a full library for functional screening, the scientific team at Creative Biogene can help you design the right strategy—from sequence design through QC-verified delivery. Reach out to discuss a tailored solution for your next project.
